The toolkit is the first product released under the Consensus Measures for Phenotypes and eXposures initiative, which is a three-year project aimed at developing a set of standard measures across 20 research categories related to health and common diseases.
The approximately $17 million acquisition, announced last week, will have "no impact" on Clinical Data's focus as a pharmacogenomics company, according to CEO Drew Fromkin.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
